These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 24058406)

  • 1. Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease.
    Gardai SJ; Mao W; Schüle B; Babcock M; Schoebel S; Lorenzana C; Alexander J; Kim S; Glick H; Hilton K; Fitzgerald JK; Buttini M; Chiou SS; McConlogue L; Anderson JP; Schenk DB; Bard F; Langston JW; Yednock T; Johnston JA
    PLoS One; 2013; 8(8):e71634. PubMed ID: 24058406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infiltrating T lymphocytes reduce myeloid phagocytosis activity in synucleinopathy model.
    Sommer A; Fadler T; Dorfmeister E; Hoffmann AC; Xiang W; Winner B; Prots I
    J Neuroinflammation; 2016 Jun; 13(1):174. PubMed ID: 27364890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.
    Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F
    Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Immune Activation by Pathologic α-Synuclein in Parkinson's Disease.
    Grozdanov V; Bousset L; Hoffmeister M; Bliederhaeuser C; Meier C; Madiona K; Pieri L; Kiechle M; McLean PJ; Kassubek J; Behrends C; Ludolph AC; Weishaupt JH; Melki R; Danzer KM
    Ann Neurol; 2019 Oct; 86(4):593-606. PubMed ID: 31343083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants.
    Roodveldt C; Labrador-Garrido A; Gonzalez-Rey E; Fernandez-Montesinos R; Caro M; Lachaud CC; Waudby CA; Delgado M; Dobson CM; Pozo D
    PLoS One; 2010 Oct; 5(10):e13481. PubMed ID: 21048992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological features of alpha-synuclein in Parkinson's disease.
    Roodveldt C; Christodoulou J; Dobson CM
    J Cell Mol Med; 2008 Oct; 12(5B):1820-9. PubMed ID: 18671754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of mutant alpha-synuclein modulates microglial phenotype in vitro.
    Rojanathammanee L; Murphy EJ; Combs CK
    J Neuroinflammation; 2011 May; 8():44. PubMed ID: 21554732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immune system in Parkinson's disease: what we know so far.
    Roodveldt C; Bernardino L; Oztop-Cakmak O; Dragic M; Fladmark KE; Ertan S; Aktas B; Pita C; Ciglar L; Garraux G; Williams-Gray C; Pacheco R; Romero-Ramos M
    Brain; 2024 Oct; 147(10):3306-3324. PubMed ID: 38833182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease.
    Wijeyekoon RS; Kronenberg-Versteeg D; Scott KM; Hayat S; Kuan WL; Evans JR; Breen DP; Cummins G; Jones JL; Clatworthy MR; Floto RA; Barker RA; Williams-Gray CH
    Brain Behav Immun; 2020 Jul; 87():473-488. PubMed ID: 32006615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease.
    Lastres-Becker I; Ulusoy A; Innamorato NG; Sahin G; Rábano A; Kirik D; Cuadrado A
    Hum Mol Genet; 2012 Jul; 21(14):3173-92. PubMed ID: 22513881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A possible role for humoral immunity in the pathogenesis of Parkinson's disease.
    Orr CF; Rowe DB; Mizuno Y; Mori H; Halliday GM
    Brain; 2005 Nov; 128(Pt 11):2665-74. PubMed ID: 16219675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibodies to alpha-synuclein in inherited Parkinson's disease.
    Papachroni KK; Ninkina N; Papapanagiotou A; Hadjigeorgiou GM; Xiromerisiou G; Papadimitriou A; Kalofoutis A; Buchman VL
    J Neurochem; 2007 May; 101(3):749-56. PubMed ID: 17448146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptor 2 is increased in neurons in Parkinson's disease brain and may contribute to alpha-synuclein pathology.
    Dzamko N; Gysbers A; Perera G; Bahar A; Shankar A; Gao J; Fu Y; Halliday GM
    Acta Neuropathol; 2017 Feb; 133(2):303-319. PubMed ID: 27888296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
    Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
    J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune responses to oligomeric α-synuclein in Parkinson's disease peripheral blood mononuclear cells.
    Vega-Benedetti AF; Porcedda C; Ercoli T; Fusco G; Burgaletto C; Pillai R; Palmas F; Cantone AF; Angius F; Solla P; De Simone A; Cantarella G; Giallongo C; Sogos V; Defazio G; Carta AR
    J Neurol; 2024 Sep; 271(9):5916-5929. PubMed ID: 38985290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease.
    Park JY; Paik SR; Jou I; Park SM
    Glia; 2008 Aug; 56(11):1215-23. PubMed ID: 18449945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T Mutant.
    Hoenen C; Gustin A; Birck C; Kirchmeyer M; Beaume N; Felten P; Grandbarbe L; Heuschling P; Heurtaux T
    PLoS One; 2016; 11(9):e0162717. PubMed ID: 27622765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCL12 is involved in α-synuclein-triggered neuroinflammation of Parkinson's disease.
    Li Y; Niu M; Zhao A; Kang W; Chen Z; Luo N; Zhou L; Zhu X; Lu L; Liu J
    J Neuroinflammation; 2019 Dec; 16(1):263. PubMed ID: 31831012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation.
    Zhang QS; Heng Y; Yuan YH; Chen NH
    Toxicol Lett; 2017 Jan; 265():30-37. PubMed ID: 27865851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.